



NUMICO

Press Release
Trading Statement Third Quarter 2007

Continued Strong Top Line Performance in Q3

7 November 2007

SALES PERFORMANCE *(on a comparable basis¹)*

TOTAL NUMICO

(€ mln)	Sales			Sales		
	Q3 07	Q3 06	change ¹	9M 07	9M 06	change ¹
Baby Food	523	469	12.2	1,536	1,385	11.7
Clinical Nutrition	200	186	14.0	583	543	14.5
Numico continued	723	654	12.7	2,119	1,927	12.5
Business to be divested	-	3	-	8	6	-
Total Numico	723	657	-	2,127	1,933	-

Reported sales increased 10.1% to €723 mln in the third quarter of 2007. This growth consisted of 12.7% organic growth which was driven by 9.2% in volume and 3.5% in price/mix. Change in business scope and currency translation effects negatively impacted reported growth by (1.9)% and (0.7)%, respectively.

In the first nine months, reported sales increased 9.6% to €2,127 mln. This growth consisted of 12.5% organic growth which was driven by 9.2% in volume and 3.3% in price/mix. Change in business scope and currency translation effects negatively impacted reported growth by (1.9)% and (1.0)%, respectively.

Numico intends to offset the negative impact of higher raw material prices through price increases and various cost savings initiatives. Price increases in Baby Food are being successfully implemented across most regions. The implementation of various cost savings initiatives is also on track. Numico remains confident that the intended price increases and savings in the variable cost base will be able to offset the negative impact of higher raw material prices in 2007.

BABY FOOD

Baby Food sales increased organically by 12.2% in the third quarter of 2007. This growth was driven by 8.2% in volume and 4.0% in price/mix.

In the first nine months, Baby Food sales increased organically by 11.7% to €1,536 mln. Growth in Western Europe accelerated from 3% in 2006 to 4% in the first nine months of 2007. This performance was driven by continued high growth in the UK and Ireland and accelerating growth in Italy and Belgium, which was partly offset by continued underperformance in France. Asia Pacific and the Rest of the World grew by 16% and 24%, respectively, with particularly strong growth in Russia, Indonesia, Turkey and Vietnam.

¹ 'Comparable basis' is at constant scope of consolidation and constant exchange rates and excluding exceptionals

CLINICAL NUTRITION

Sales in Clinical Nutrition grew organically by 14.0% in the third quarter of 2007. This growth was driven by 11.4% in volume and 2.6% in price/mix.

In the first nine months of 2007, sales in Clinical Nutrition grew organically by 14.5% to €583 mln. Growth was supported across all regions with growth in Northern Europe at 12%, Southern Europe at 15% and Rest of the World at 21%. This strong growth performance reflects the division's increased focus and enhanced business model as well as the complete recovery of the German market. Especially France, Brazil and most of the Eastern European countries delivered particularly strong performances.

OUTLOOK

Based on the strong potential of the markets in which Numico operates, the company reconfirms that it expects total sales to grow organically between 10 - 12% and the EBITA margin to improve between 10 and 20 bps in 2007. These targets are all based on constant scope of consolidation, constant exchange rates, excluding exceptionals and barring unforeseen circumstances.

WARNING ABOUT FORWARD-LOOKING STATEMENTS

Some statements in this document are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. These forward-looking statements involve known and unknown risks, uncertainties and other factors that are outside of our control and impossible to predict and may cause actual results to differ materially from any future results expressed or implied.

These forward-looking statements are based on current expectations, estimates, forecasts and projections and our beliefs and assumptions about future events. Forward-looking statements include, without limitation, statements concerning Numico's results or financial position and the other factors discussed in the company's annual report. An overview of the most important financial factors that may affect Numico's results are provided in the company's most recent Annual Report.

Given these uncertainties, no assurance can be given as to Numico's future results or financial position. You are cautioned not to put undue reliance on these forward-looking statements, which only speak as of the date of this document and are neither predictions nor guarantees of future events or circumstances. Numico does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

It is to be noted that all numbers in this report are unaudited.

For any questions you might have, please contact:

Groupe Danone: Press Office
Groupe Danone: Investor Relations

tel. +33 (0)1 44 35 20 75 / +33 (0)1 44 35 39 99
tel. +33 (0)1 44 35 20 76

Royal Numico N.V. Corporate Communications
Royal Numico N.V. Investor Relations

tel. +31 20 456 9077
tel. +31 20 456 9032